Clinical Trial

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants

Study acronym: MOONRISE
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-12-31 -> 2026-06-30 2026-05-19
minor Completion moved earlier: 2027-12-31 -> 2026-06-30 2026-05-19
Trial Details
NCT Number NCT04614714
Lead Sponsor University of California, Davis
Collaborators: ChromaDex, Inc.
Conditions Preterm Birth, Inadequate Milk Production
Enrollment 40 participants
Start Date 2026-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-18